Simpler Grants.gov #RFA-CA-20-002 and RFA-CA-20-003

Forecasted funding opportunity for biospecimen banking resources supporting NCI clinical trials

This forecasted opportunity from the National Cancer Institute (NCI) aims to support biospecimen banking resources for NCI-funded clinical trials. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Services Requested: - Continuation of biospecimen banking operations for: - National Clinical Trials Network (NCTN) Biospecimen Banks - Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) - Services include collection, processing, storage, and distribution of clinically annotated human biospecimens - Support for translational cancer research, biomarker development, and scientific discovery - Eligibility: - Only current recipients of NCTN or EET biobank awards funded under previous RFAs may apply - Unique Requirements: - Focus on maintaining national biobanking resources for large multi-site and early-phase clinical trials - No specific OEMs or commercial products are mentioned; the procurement is for specialized biobanking services - No product line items or part numbers are specified; the opportunity centers on service delivery and resource maintenance

Description

The National Cancer Institute (NCI) is soliciting applications through a limited competition Notice of Funding Opportunity (NOFO) to support continuation of two biospecimen banking resources: the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). These resources support the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens from NCI-funded clinical trials focused on cancer treatment, prevention, and control. The NCTN Biobanks support biobanking operations for large multi-site clinical trials, while the EET Biobank focuses on early-phase and experimental clinical trials involving investigational new drugs. Applications will be peer-reviewed and funded if meritorious, but are not currently being solicited to allow time for collaboration development.

View original listing